We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Paratek Reports Positive Phase III Data on Antibiotic Drug
Read MoreHide Full Article
Paratek Pharmaceuticals, Inc. announced positive results from a phase III study (OASIS) comparing its antibiotic candidate omadacycline to Pfizer Inc.’s (PFE - Free Report) Zyvox for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
The OASIS study evaluated the efficacy and safety of an intravenous to oral once-daily dose of omadacycline against a twice daily dose of Zyvox.
Results showed that the study met the FDA specified primary efficacy endpoint of early clinical response (ECR). The ECR for omadacycline was found to be 84.8% as compared to Zyvox which stood at 85.5%. Additionally, the study met two European Medicines Agency specified co-primary efficacy endpoints for post-treatment evaluation. The candidate was found to be safe and well-tolerated.
Paratek intends to present results from this study along with data for the secondary endpoints at an upcoming scientific congress.
Apart from ABSSSI, Paratek is also conducting additional studies on omadacycline for other indications. The company expects to announce top-line data from a phase III study comparing omadacycline to Bayer AG’s (BAYRY - Free Report) Avelox for the treatment of community acquired bacterial pneumonia (CABP) as early as the third quarter of 2017. Last month, Paratek initiated a phase Ib study on omadacycline for the treatment of urinary tract infections.
Paratek plans to submit a new drug application for omadacycline for the treatment of both ABSSSI and CABP in the first half of 2018. We note that omadacycline enjoys Fast Track status in the U.S.
Other than omadacycline, another advanced candidate in the company’s pipeline is sarecycline. It is currently in phase III studies for the treatment of moderate-to-severe acne vulgaris. While Allergan plc has development and commercialization rights to sarecycline in the U.S., all ex-U.S. rights are with Paratek.
Paratek is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Pfizer, sporting a Zacks Rank #1 (Strong Buy) and Bayer, carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Paratek Reports Positive Phase III Data on Antibiotic Drug
Paratek Pharmaceuticals, Inc. announced positive results from a phase III study (OASIS) comparing its antibiotic candidate omadacycline to Pfizer Inc.’s (PFE - Free Report) Zyvox for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
The OASIS study evaluated the efficacy and safety of an intravenous to oral once-daily dose of omadacycline against a twice daily dose of Zyvox.
Results showed that the study met the FDA specified primary efficacy endpoint of early clinical response (ECR). The ECR for omadacycline was found to be 84.8% as compared to Zyvox which stood at 85.5%. Additionally, the study met two European Medicines Agency specified co-primary efficacy endpoints for post-treatment evaluation. The candidate was found to be safe and well-tolerated.
Paratek intends to present results from this study along with data for the secondary endpoints at an upcoming scientific congress.
Apart from ABSSSI, Paratek is also conducting additional studies on omadacycline for other indications. The company expects to announce top-line data from a phase III study comparing omadacycline to Bayer AG’s (BAYRY - Free Report) Avelox for the treatment of community acquired bacterial pneumonia (CABP) as early as the third quarter of 2017. Last month, Paratek initiated a phase Ib study on omadacycline for the treatment of urinary tract infections.
Paratek plans to submit a new drug application for omadacycline for the treatment of both ABSSSI and CABP in the first half of 2018. We note that omadacycline enjoys Fast Track status in the U.S.
Other than omadacycline, another advanced candidate in the company’s pipeline is sarecycline. It is currently in phase III studies for the treatment of moderate-to-severe acne vulgaris. While Allergan plc has development and commercialization rights to sarecycline in the U.S., all ex-U.S. rights are with Paratek.
Paratek is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Pfizer, sporting a Zacks Rank #1 (Strong Buy) and Bayer, carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>